HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Groshar, D. Articles by Chapman, J. D. Search for Related Content PubMed PubMed Citation Articles by Groshar, D. Articles by Chapman, J. D.

Imaging Tumor Hypoxia and Tumor Perfusion

Cross Cancer Institute, Edmonton, Alberta, Canada
Rebecca Sief Government Hospital, Safed, Israel
University of Alberta, Edmonton, Alberta, Canada
Fox Chase Cancer Center, Philadelphia, Pennsylvania

Correspondence: For correspondence or reprints: Dr. A.J.B. McEwan, Dept. of Nuclear Medicine, Cross Cancer Institute, 11560 University Ave., Edmonton, Alberta, Canada T8G 1Z2.

ABSTRACT

Tumor perfusion and oxygenation status have been suggested as factors which may influence treatment outcome in cancer patients. Nuclear medicine assays of tumor perfusion [^99mTc-hexamethylpropylenamine oxime (HMPAO) and tumor hypoxia [¹²³I-iodoazomycin arabinoside (IAZA)] have recently been developed and described. We report on measurements of perfusion and oxygenation status of 27 tumors in 22 patients using these probes. An inverse correlation between tumor uptake of HMPAO and IAZA was measured (p < 0.05), with severe perfusion deficit usually associated with an increased uptake of the hypoxic marker. This trend was observed for limited stage small-cell lung carcinoma, squamous-cell carcinoma of the head and neck, soft-tissue sarcoma, brain metastases from small-cell lung carcinoma and adenocarcinoma of the prostate as a group, but not for glioblastoma multiforme. Whereas each imaging agent can yield information about the physiological status of tumor and normal tissue, the information resulting from their combined use could be important in cancer therapy.

This article has been cited by other articles:

				M. Takasawa, R. R. Moustafa, and J.-C. Baron Applications of Nitroimidazole In Vivo Hypoxia Imaging in Ischemic Stroke Stroke, May 1, 2008; 39(5): 1629 - 1637. [Abstract] [Full Text] [PDF]

				G S Stamatakos, V P Antipas, N K Uzunoglu, and R G Dale A four-dimensional computer simulation model of the in vivo response to radiotherapy of glioblastoma multiforme: studies on the effect of clonogenic cell density Br. J. Radiol., May 1, 2006; 79(941): 389 - 400. [Abstract] [Full Text] [PDF]

				D. Gandhi, D.B. Chepeha, T. Miller, R.C. Carlos, C.R. Bradford, R. Karamchandani, F. Worden, A. Eisbruch, T.N. Teknos, G.T. Wolf, et al. Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. AJNR Am. J. Neuroradiol., January 1, 2006; 27(1): 101 - 106. [Abstract] [Full Text] [PDF]

				M. Bruehlmeier, U. Roelcke, P. A. Schubiger, and S. M. Ametamey Assessment of Hypoxia and Perfusion in Human Brain Tumors Using PET with 18F-Fluoromisonidazole and 15O-H2O J. Nucl. Med., November 1, 2004; 45(11): 1851 - 1859. [Abstract] [Full Text] [PDF]

				J. S. Lewis, P. Herrero, T. L. Sharp, J. A. Engelbach, Y. Fujibayashi, R. Laforest, A. Kovacs, R. J. Gropler, and M. J. Welch Delineation of Hypoxia in Canine Myocardium Using PET and Copper(II)-Diacetyl-bis(N4-Methylthiosemicarbazone) J. Nucl. Med., November 1, 2002; 43(11): 1557 - 1569. [Abstract] [Full Text] [PDF]

				K. Lehtio, V. Oikonen, T. Gronroos, O. Eskola, K. Kalliokoski, J. Bergman, O. Solin, R. Grenman, P. Nuutila, and H. Minn Imaging of Blood Flow and Hypoxia in Head and Neck Cancer: Initial Evaluation with [15O]H2O and [18F]Fluoroerythronitroimidazole PET J. Nucl. Med., November 1, 2001; 42(11): 1643 - 1652. [Abstract] [Full Text] [PDF]

				J. D. Chapman, P. Zanzonico, and C. C. Ling On Measuring Hypoxia in Individual Tumors with Radiolabeled Agents J. Nucl. Med., November 1, 2001; 42(11): 1653 - 1655. [Full Text] [PDF]

				T. Gronroos, O. Eskola, K. Lehtio, H. Minn, P. Marjamaki, J. Bergman, M. Haaparanta, S. Forsback, and O. Solin Pharmacokinetics of [18F]FETNIM: A Potential Hypoxia Marker for PET J. Nucl. Med., September 1, 2001; 42(9): 1397 - 1404. [Abstract] [Full Text] [PDF]

				D. Stypinski, S. A. McQuarrie, L. I. Wiebe, Y. K. Tam, J. R. Mercer, and A. J.B. McEwan Dosimetry Estimations for 123I-IAZA in Healthy Volunteers J. Nucl. Med., September 1, 2001; 42(9): 1418 - 1423. [Abstract] [Full Text] [PDF]

				M. Hockel and P. Vaupel Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects J Natl Cancer Inst, February 21, 2001; 93(4): 266 - 276. [Abstract] [Full Text] [PDF]

				R. D. Okada, G. Johnson III, K. N. Nguyen, B. Edwards, C. M. Archer, and J. D. Kelly 99mTc-HL91 : Effects of Low Flow and Hypoxia on a New Ischemia-Avid Myocardial Imaging Agent Circulation, April 1, 1997; 95(7): 1892 - 1899. [Abstract] [Full Text]